RVLPQ — RVL Pharmaceuticals Share Price
0.000.00%
Last trade - 00:00- $0.00m
- $38.61m
- $49.72m
- 35
- 86
- 23
- 46
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0 | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 0 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -416.07% | ||
| Return on Equity | -182.44% | ||
| Operating Margin | -191.72% | ||
Financial Summary
| Year End 31st Dec | Unit | 2018 | 2019 | 2020 | 2021 | 2022 | 2023E | 2024E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 263.7 | 240.03 | 177.88 | 17.5 | 49.72 | 35.55 | 52.62 | -27.35% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
RVL Pharmaceuticals plc is a specialty pharmaceutical company. The Company is focused on the commercialization of UPNEEQ, or RVL-1201 (oxymetazoline hydrochloride ophthalmic solution), 0.1%, for the treatment of acquired blepharoptosis, or low-lying eyelid, in adults. It is focused on growing Upneeq with eye care and medical aesthetic professionals and providing a prescription experience for patients through its pharmacy. RVL Pharmacy dispenses Upneeq only. The Company is also developing Arbaclofen ER tablets for the alleviation of spasticity in multiple sclerosis patients. Its target patient population comprises adults with droopy or low-lying eyelids or acquired ptosis, the majority of whom are female. Its healthcare provider customers include optometrists, ophthalmologists, oculoplastic surgeons, facial plastic surgeons, dermatologists, and practitioners qualified to diagnose and treat acquired blepharoptosis in adults.
Directors
- Brian Markison CHM (61)
- Andrew Einhorn CFO (61)
- James Schaub COO (39)
- Tina deVries EVP (60)
- Christopher Klein GCN (57)
- Joachim Benes DRC (32)
- David Burgstahler DRC (52)
- Sriram Venkataraman DRC (48)
- Juan Vergez DRC (62)
- Gregory Cowan IND (67)
- Michael DeBiasi IND (45)
- Last Annual
- December 31st, 2022
- Last Interim
- June 30th, 2023
- Incorporated
- July 13th, 2017
- Public Since
- October 12th, 2018
- No. of Shareholders
- 3
- No. of Employees
- 125
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- Pink Sheets on Nasdaq
- Shares in Issue
- 111,406,043
- Address
- 400 CROSSING BOULEVARD, BRIDGEWATER, 08807
- Web
- https://www.rvlpharma.com/
- Phone
- +1 9088091300
- Contact
- Lisa Wilson
- Auditors
- Ernst & Young LLP
Upcoming Events for RVLPQ
RVL Pharmaceuticals PLC Annual Shareholders Meeting
Q2 2024 RVL Pharmaceuticals PLC Earnings Release
Similar to RVLPQ
Acusphere
Pink Sheets on Nasdaq
Adorbs
Pink Sheets on Nasdaq
Agentix
Pink Sheets on Nasdaq
Agrios Global Holdings
Pink Sheets on Nasdaq
Aida Pharmaceuticals
Pink Sheets on Nasdaq
FAQ
What is the RVL Pharmaceuticals share price?
As of Today at 23:02 UTC, shares in RVL Pharmaceuticals are trading at $0.00. This share price information is delayed by 15 minutes.
How has the RVL Pharmaceuticals share price performed this year?
Shares in RVL Pharmaceuticals last closed at $0.00 and the price had moved by -100% over the past 365 days. In terms of relative price strength the RVL Pharmaceuticals share price has underperformed the S&P500 Index by -100% over the past year.
What are the analyst and broker recommendations for RVL Pharmaceuticals?
The overall consensus recommendation for RVL Pharmaceuticals is Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the RVL Pharmaceuticals dividend yield?
RVL Pharmaceuticals does not currently pay a dividend.
Does RVL Pharmaceuticals pay a dividend?
RVL Pharmaceuticals does not currently pay a dividend.
When does RVL Pharmaceuticals next pay dividends?
RVL Pharmaceuticals does not currently pay a dividend.
How do I buy RVL Pharmaceuticals shares?
To buy shares in RVL Pharmaceuticals you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of RVL Pharmaceuticals?
As of the previous close price of $0.00, shares in RVL Pharmaceuticals had a market capitalisation of $0.00m.
Where are RVL Pharmaceuticals shares listed?
Here are the trading details for RVL Pharmaceuticals:
- Country of listing: United States
- Exchange: PNK
- Ticker Symbol: RVLPQ
What kind of share is RVL Pharmaceuticals?
Based on an overall assessment of its quality, value and momentum RVL Pharmaceuticals is currently classified as a Value Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a RVL Pharmaceuticals share price forecast for 2024?
The analyst consensus target price for shares in RVL Pharmaceuticals is $1.60. That is 159999900% above the last closing price of $0.00.
Analysts covering RVL Pharmaceuticals currently have a consensus Earnings Per Share (EPS) forecast of -$0.57 for the next financial year.
What is the trend in the RVL Pharmaceuticals share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like RVL Pharmaceuticals. Over the past six months, its share price has underperformed the S&P500 Index by -99.96%.
As of the last closing price of $0.00, shares in RVL Pharmaceuticals were trading -100% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the RVL Pharmaceuticals PE Ratio?
The RVL Pharmaceuticals PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.00.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of RVL Pharmaceuticals?
RVL Pharmaceuticals' management team is headed by:
- Brian Markison - CHM
- Andrew Einhorn - CFO
- James Schaub - COO
- Tina deVries - EVP
- Christopher Klein - GCN
- Joachim Benes - DRC
- David Burgstahler - DRC
- Sriram Venkataraman - DRC
- Juan Vergez - DRC
- Gregory Cowan - IND
- Michael DeBiasi - IND